Literature DB >> 24890952

Helicobacter pylori antimicrobial resistance rates in the central region of Portugal.

N Almeida1, J M Romãozinho, M M Donato, C Luxo, O Cardoso, M A Cipriano, C Marinho, A Fernandes, C Calhau, C Sofia.   

Abstract

Helicobacter pylori resistance to antimicrobial agents is steadily increasing. It is extremely important to be aware of the local prevalence of antibiotic resistance so as to adjust treatment strategies. During this single-centre, prospective study, we aimed to determine primary and secondary resistance rates of H. pylori to antibiotics as well as host and bacterial factors associated with this problem. Overall, 180 patients (131 female; mean age 43.4±13.5 years; primary resistance 103; secondary resistance 77) with positive (13) C-urea breath test were submitted to upper endoscopy with gastric biopsies. Helicobacter pylori was cultured and antimicrobial susceptibility was determined by Etest and molecular methods. Clinical and microbiological characteristics associated with resistance were evaluated by logistic regression analysis. Among the 180 isolates 50% were resistant to clarithromycin (primary 21.4%; secondary 88.3%), 34.4% to metronidazole (primary 29.1%; secondary 41.6%), 33.9% to levofloxacin (primary 26.2%; secondary 44.2%), 0.6% to tetracycline and 0.6% to amoxicillin. Being female was an independent predictor of resistance to clarithromycin and metronidazole. Previous, failed, eradication treatments were also associated with a decrease in susceptibility to clarithromycin. History of frequent infections, first-degree relatives with gastric carcinoma and low education levels determined increased resistance to levofloxacin. Mutations in the 23S rRNA and gyrA genes were frequently found in isolates with resistance to clarithromycin and levofloxacin, respectively. This study revealed that resistance rates to clarithromycin, metronidazole and levofloxacin are very high and may compromise H. pylori eradication with first-line and second-line empiric triple treatments in Portugal.
© 2014 The Authors Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Keywords:  Antibiotics; Helicobacter pylori; multidrug resistant; mutations 23S rRNA; mutations gyrA; primary resistance; secondary resistance

Mesh:

Substances:

Year:  2014        PMID: 24890952     DOI: 10.1111/1469-0691.12701

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  11 in total

1.  Occurrence of Mutations in the Antimicrobial Target Genes Related to Levofloxacin, Clarithromycin, and Amoxicillin Resistance in Helicobacter pylori Isolates from Buenos Aires City.

Authors:  Gerardo Zerbetto De Palma; Nicolas Mendiondo; Andrés Wonaga; Luis Viola; Daniela Ibarra; Esteban Campitelli; Nicolas Salim; Rodolfo Corti; Cinthia Goldman; Mariana Catalano
Journal:  Microb Drug Resist       Date:  2016-07-08       Impact factor: 3.431

2.  Point Mutations at gyrA and gyrB Genes of Levofloxacin-Resistant Helicobacter pylori Isolates in the Esophageal Mucosa from a Venezuelan Population.

Authors:  Mariela López-Gasca; Jessy Peña; María-Alexandra García-Amado; Fabián Michelangeli; Monica Contreras
Journal:  Am J Trop Med Hyg       Date:  2018-02-01       Impact factor: 2.345

3.  Low efficacy of levofloxacin-doxycycline-based third-line triple therapy for Helicobacter pylori eradication in Italy.

Authors:  Omero Alessandro Paoluzi; Giovanna Del Vecchio Blanco; Emanuela Visconti; Manuela Coppola; Carla Fontana; Marco Favaro; Francesco Pallone
Journal:  World J Gastroenterol       Date:  2015-06-07       Impact factor: 5.742

Review 4.  Prevalence of antibiotic resistance in Helicobacter pylori: A recent literature review.

Authors:  Reza Ghotaslou; Hamed Ebrahimzadeh Leylabadlo; Yalda Mohammadzadeh Asl
Journal:  World J Methodol       Date:  2015-09-26

5.  Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics?

Authors:  Diogo Branquinho; Nuno Almeida; Carlos Gregório; José Eduardo Pina Cabral; Adriano Casela; Maria Manuel Donato; Luís Tomé
Journal:  BMC Gastroenterol       Date:  2017-02-15       Impact factor: 3.067

6.  Increase in antibiotic resistant Helicobacter pylori in a University Hospital in Japan.

Authors:  Chihiro Kageyama; Mayu Sato; Hiroyuki Sakae; Yuka Obayashi; Yoshiro Kawahara; Takehiko Mima; Osamu Matsushita; Kenji Yokota; Motowo Mizuno; Hiroyuki Okada
Journal:  Infect Drug Resist       Date:  2019-03-12       Impact factor: 4.003

7.  Association between H. pylori infection and health Outcomes: an umbrella review of systematic reviews and meta-analyses.

Authors:  Liqun Li; Jinjing Tan; Lijian Liu; Jianfeng Li; Guangwen Chen; Mingbing Chen; Jieru Xie; Qingzeng Song; Xiaoyan Huang; Sheng Xie
Journal:  BMJ Open       Date:  2020-01-09       Impact factor: 2.692

8.  Primary and secondary clarithromycin resistance in Helicobacter pylori and mathematical modeling of the role of macrolides.

Authors:  Éva Kocsmár; György Miklós Buzás; Ildikó Szirtes; Ildikó Kocsmár; Zsófia Kramer; Attila Szijártó; Petra Fadgyas-Freyler; Kató Szénás; Massimo Rugge; Matteo Fassan; András Kiss; Zsuzsa Schaff; Gergely Röst; Gábor Lotz
Journal:  Nat Commun       Date:  2021-04-15       Impact factor: 14.919

Review 9.  Quinolone-containing therapies in the eradication of Helicobacter pylori.

Authors:  Seng-Kee Chuah; Wei-Chen Tai; Chen-Hsiang Lee; Chih-Ming Liang; Tsung-Hui Hu
Journal:  Biomed Res Int       Date:  2014-08-28       Impact factor: 3.411

10.  High Primary Antibiotic Resistance of Helicobacter pylori Strains Isolated from Pediatric and Adult Patients in Poland during 2016-2018.

Authors:  Paweł Krzyżek; Dorota Pawełka; Barbara Iwańczak; Radosław Kempiński; Konrad Leśniakowski; Francis Mégraud; Łukasz Łaczmański; Monika Biernat; Grażyna Gościniak
Journal:  Antibiotics (Basel)       Date:  2020-05-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.